Our results suggested that overexpression of 11β-HSD1 induced lipid accumulation, at least partially through the GR/gp78/Insig2/SREBP1 pathway, which may serve as a potential diagnostic and therapeutic target for treatment of NAFLD. The gene discussed is NR3C1; the disease is metabolic dysfunction-associated steatotic liver disease.